vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $12.2M, roughly 1.5× Village Farms International, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs -0.8%, a 20.7% gap on every dollar of revenue. On growth, Village Farms International, Inc. posted the faster year-over-year revenue change (31.5% vs -25.7%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
CTMX vs VFF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $12.2M |
| Net Profit | $-154.0K | $2.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | 19.9% |
| Revenue YoY | -25.7% | 31.5% |
| Net Profit YoY | 97.6% | 128.2% |
| EPS (diluted) | — | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $66.7M | ||
| Q2 25 | $18.7M | $59.9M | ||
| Q1 25 | $50.9M | $77.1M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $54.9M | ||
| Q2 24 | $25.1M | $53.6M | ||
| Q1 24 | $41.5M | $78.1M |
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $10.2M | ||
| Q2 25 | $-154.0K | $26.5M | ||
| Q1 25 | $23.5M | $-6.7M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-820.0K | ||
| Q2 24 | $-6.5M | $-23.5M | ||
| Q1 24 | $13.8M | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 47.9% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 14.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 24.8% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 19.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.3% | ||
| Q2 25 | -6.9% | 20.8% | ||
| Q1 25 | 44.4% | -8.0% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | 3.8% | ||
| Q2 24 | -33.7% | -43.5% | ||
| Q1 24 | 28.1% | -3.0% |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | -0.8% | 44.2% | ||
| Q1 25 | 46.2% | -8.7% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -1.5% | ||
| Q2 24 | -26.0% | -43.9% | ||
| Q1 24 | 33.3% | -3.7% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $0.08 | ||
| Q2 25 | — | $0.24 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.01 | ||
| Q2 24 | — | $-0.21 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $81.2M |
| Total DebtLower is stronger | — | $33.7M |
| Stockholders' EquityBook value | $119.9M | $299.9M |
| Total Assets | $175.1M | $423.1M |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $81.2M | ||
| Q3 25 | — | $82.6M | ||
| Q2 25 | $49.0M | $60.0M | ||
| Q1 25 | $47.6M | $15.1M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $28.7M | ||
| Q2 24 | $43.2M | $29.7M | ||
| Q1 24 | $36.2M | $26.7M |
| Q4 25 | — | $33.7M | ||
| Q3 25 | — | $34.6M | ||
| Q2 25 | — | $39.1M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $43.3M | ||
| Q2 24 | — | $44.4M | ||
| Q1 24 | — | $46.1M |
| Q4 25 | — | $299.9M | ||
| Q3 25 | — | $295.4M | ||
| Q2 25 | $119.9M | $284.3M | ||
| Q1 25 | $25.0M | $248.3M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $274.4M | ||
| Q2 24 | $-31.2M | $275.2M | ||
| Q1 24 | $-31.7M | $296.2M |
| Q4 25 | — | $423.1M | ||
| Q3 25 | — | $418.4M | ||
| Q2 25 | $175.1M | $403.7M | ||
| Q1 25 | $98.5M | $377.1M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $417.8M | ||
| Q2 24 | $159.2M | $425.4M | ||
| Q1 24 | $184.7M | $458.4M |
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | — |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | 90.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $24.4M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.0M | $-6.4M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | $4.3M | ||
| Q2 24 | $-19.5M | $5.7M | ||
| Q1 24 | $-26.0M | $-50.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $22.6M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | $-8.9M | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | $1.5M | ||
| Q2 24 | $-19.6M | $4.8M | ||
| Q1 24 | $-26.2M | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 33.9% | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | -11.6% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | 2.7% | ||
| Q2 24 | -78.2% | 9.0% | ||
| Q1 24 | -63.1% | -2.5% |
| Q4 25 | — | 90.8% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | 0.1% | 4.6% | ||
| Q1 25 | 0.2% | 3.3% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | 5.1% | ||
| Q2 24 | 0.4% | 1.6% | ||
| Q1 24 | 0.3% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
